Page last updated: 2024-12-05

2-methoxy-1,4-naphthoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methoxy-1,4-naphthoquinone: isolated from Swertia calycina; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methoxy-1,4-naphthoquinone : A naphthoquinone that is naphthalene-1,4-dione substituted by a methoxy group at position 2. It has been isolated from the roots of Rubia yunnanensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
RubiagenusA plant genus of the family RUBIACEAE. The root is a source of red dyes (madder color and 1,2,4-trihydroxy-9,10-anthracenedione) and ANTHRAQUINONES.[MeSH]RubiaceaeThe Madder plant family of the order Gentianales (formerly Rubiales), subclass Asteridae, class Magnoliopsida includes important medicinal plants that provide QUININE; IPECAC; and COFFEE. They have opposite leaves and interpetiolar stipules.[MeSH]
SwertiagenusA plant genus of the family GENTIANACEAE. It is a source of swertiapuniside and IRIDOID GLYCOSIDES.[MeSH]GentianaceaeA plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH]

Cross-References

ID SourceID
PubMed CID16871
CHEMBL ID106562
CHEBI ID69522
SCHEMBL ID571061
MeSH IDM0252966

Synonyms (46)

Synonym
2-methoxy-naphthalene-1,4-dione
1,4-naphthalenedione, 2-methoxy-
1,4-naphthoquinone, 2-methoxy-
2-methoxy-1,4-naphthoquinone
nsc31530
nsc-31530
2348-82-5
2-methoxy-p-naphthoquinone
nsc 31530
ai3-17893
2-methoxynaphthoquinone
2-methoxy-1,4-naphthalenedione
2-methoxynaphthalene-1,4-dione
2-methoxy-[1,4]naphthoquinone
obgbghkyjaoxrr-uhfffaoysa-
inchi=1/c11h8o3/c1-14-10-6-9(12)7-4-2-3-5-8(7)11(10)13/h2-6h,1h3
2-methoxy-1,4-naphthoquinone, 98%
bdbm24775
2-methoxy-1,4-naphthoquinone, 2
2-methoxy-1,4-dihydronaphthalene-1,4-dione
chembl106562 ,
MLS002472995
smr000112464
chebi:69522 ,
HMS1607J05
AKOS001588285
NCGC00247463-01
unii-39020but1d
39020but1d ,
A816744
S3661
FT-0634207
SCHEMBL571061
CCG-214807
lawsone methyl ether
DTXSID1062338
2-methoxy-1,4-napthoquinone
o-methyllawsone
AS-61144
J-015127
Q27137861
CS-0030693
HY-N7116
2-ethoxy-1,4-aphthoquinone
CAA34882
EN300-332507
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
enol etherEthers ROR' where R has a double bond adjacent to the oxygen of the ether linkage.
1,4-naphthoquinonesA naphthoquinone in which the oxo groups of the quinone moiety are at positions 1 and 4 of the parent naphthalene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (28)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency39.81070.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency18.34890.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency12.58930.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency3.88600.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency1.41250.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency17.03900.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency11.58210.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency35.48133.548119.542744.6684AID743266
flap endonuclease 1Homo sapiens (human)Potency10.00000.133725.412989.1251AID588795
DNA polymerase eta isoform 1Homo sapiens (human)Potency79.43280.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency14.12540.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency5.01190.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency12.43470.004611.374133.4983AID624296; AID624297
VprHuman immunodeficiency virus 1Potency22.38721.584919.626463.0957AID651644
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency11.22020.058010.694926.6086AID602310
Glycoprotein hormones alpha chainHomo sapiens (human)Potency31.62284.46688.344810.0000AID624291
TAR DNA-binding protein 43Homo sapiens (human)Potency19.95261.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)0.72000.05373.075710.0000AID1798473; AID326467
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)22.60000.00002.37899.7700AID1801570
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)2.30000.02204.20249.4000AID1517763
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)46.80000.10002.31039.5100AID1517765
Carbonic anhydrase 2Mycobacterium tuberculosis H37RvIC50 (µMol)2.30001.20001.75002.3000AID1416033
Genome polyprotein Human rhinovirus sp.IC50 (µMol)26.00000.00052.98388.2000AID163631
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)IC50 (µMol)200.00000.00202.52666.0800AID1667745
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (78)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
DNA damage responseHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin remodelingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3K4 monomethyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleolusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (66)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1517772Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1416034Binding affinity to recombinant Mycobacterium tuberculosis Rv1284 expressed in Escherichia coli BL21-Al cells assessed as change in melting temperature by SYPRO Orange dye based differential scanning fluorimetric method2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID326467Inhibition of purified human recombinant IDO2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
AID1517767Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID23482Partition coefficient (logP)1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Substituted 1,4-naphthoquinones vs. the ascitic sarcoma 180 of mice.
AID1517763Inhibition of recombinant Cdc25A (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517770Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1274027Antimalarial activity against chloroquine-sensitive NF54 isolated Plasmodium falciparum 3D7 infected in erythrocytes assessed as inhibition of parasitic growth after 48 hrs by optical microscopy2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and antimalarial activity of quinones and structurally-related oxirane derivatives.
AID117228Tested for acute toxicity which is the single dose given intraperitoneally that will kill one-half of the mice within 5 days1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Substituted 1,4-naphthoquinones vs. the ascitic sarcoma 180 of mice.
AID1667745Inhibition of SET7 (unknown origin) using biotinylated histone polypeptide as substrate in presence of SAM by AlphaLISA assay2020Bioorganic & medicinal chemistry letters, 05-01, Volume: 30, Issue:9
Lead discovery, chemical optimization, and biological evaluation studies of novel histone methyltransferase SET7 small-molecule inhibitors.
AID1517773Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1754248Inhibition of recombinant Trypanosoma brucei rhodesain at 100 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID1758986Cytotoxicity against human HeLa cells2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis, biological evaluation, and correlation of cytotoxicity versus redox potential of 1,4-naphthoquinone derivatives.
AID623561Cytotoxicity against human SMMC7721 cells after 48 hrs by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis.
AID1517765Inhibition of recombinant Cdc25B (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID242681Antiproliferative activity in MTS assay in LNCaP cells after 72 hr at 1-100 uM; Inactive at 100 uM2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.
AID39233Effective dose that would give a 25% increase in the survival time against the ascitic sarcoma 180 in mice1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Substituted 1,4-naphthoquinones vs. the ascitic sarcoma 180 of mice.
AID672966Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 72 hrs by Neubauer counter-based microscopic analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID1416037Inhibition of recombinant human carbonic anhydrase 2 expressed in Escherichia coli BL21 (DE3) assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration assay relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID672967Cytotoxicity against african green monkey Vero cells after 72 hrs by spectrophotometric analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID155387Inhibitory activity against papain using HPLC assay; Not tested2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
AID402110Antipruritic activity in ddY mouse assessed as inhibition of compound 48/80-induced nose scratching behavior at 10 mg/kg, po for 20 mins preincubated 24 hrs before compound 48/80 challenge1998Journal of natural products, Sep, Volume: 61, Issue:9
Antipruritic dinaphthofuran-7,12-dione derivatives from the pericarp of Impatiens balsamina.
AID1758987Redox potential of compound in phosphate buffer at pH 7.2 by cyclic voltammetry2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis, biological evaluation, and correlation of cytotoxicity versus redox potential of 1,4-naphthoquinone derivatives.
AID1517776Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517768Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1416033Inhibition of recombinant Mycobacterium tuberculosis N-terminal Hi-tagged Rv3588c expressed in Escherichia coli BL21-Al cells measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration assay2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID1754246Inhibition of recombinant Trypanosoma cruzi cruzain at 100 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID672965Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death at 50 uM after 72 hrs by propidium iodide staining-based flow cytometric analysis2012Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16
New oxirane derivatives of 1,4-naphthoquinones and their evaluation against T. cruzi epimastigote forms.
AID1416035Inhibition of recombinant Mycobacterium tuberculosis Rv1284 expressed in Escherichia coli BL21-Al cells assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration assay relative to contr2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID1517787Binding affinity to MKK7 (unknown origin) expressed in HEK293 cells assessed as dissociation constant at <30 uM by kinomescan method2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1274028Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by alamar blue assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and antimalarial activity of quinones and structurally-related oxirane derivatives.
AID1517775Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517771Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID623564Antifungal activity against Candida albicans CGMCC 2.2086 after 24 hrs by turbidimetric method2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis.
AID1758985Cytotoxicity against human KB cells2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Synthesis, biological evaluation, and correlation of cytotoxicity versus redox potential of 1,4-naphthoquinone derivatives.
AID623528Cytotoxicity against human HeLa cells at >10 uM after 48 hrs by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis.
AID623526Cytotoxicity against human A549 cells at >10 uM after 48 hrs by SRB assay2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis.
AID242734Antioxidant activity against t-BuOOH induced ROS formation in LNCaP cells after 24 hr at 1-100 uM; Inactive at 100 uM2005Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1
Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.
AID117493Maximum survival by an optimum dose at 60 mg/kg in treated to that of untreated mice1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Substituted 1,4-naphthoquinones vs. the ascitic sarcoma 180 of mice.
AID1416036Inhibition of recombinant Mycobacterium tuberculosis N-terminal Hi-tagged Rv3588c expressed in Escherichia coli BL21-Al cells assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration a2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID163631Inhibitory activity against HRV 3Cpro using HPLC assay2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
AID21140Solubility in water was determined1983Journal of medicinal chemistry, Apr, Volume: 26, Issue:4
Substituted 1,4-naphthoquinones vs. the ascitic sarcoma 180 of mice.
AID623563Antibacterial activity against Staphylococcus aureus CGMCC1.2465 after 24 hrs by turbidimetric method2011Journal of natural products, Oct-28, Volume: 74, Issue:10
Biologically active arborinane-type triterpenoids and anthraquinones from Rubia yunnanensis.
AID1517769Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1274029Selectivity index, ratio of IC50 for MRC5 cells to IC50 for chloroquine-sensitive NF54 isolated Plasmodium falciparum 3D72016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and antimalarial activity of quinones and structurally-related oxirane derivatives.
AID1517790Inhibition of recombinant HNE (unknown origin) at <50 uM using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, as a substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1517774Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1801570MAO Inhibition Assay from Article 10.1111/cbdd.12708: \\Evaluation of Natural and Synthetic 1,4-naphthoquinones as Inhibitors of Monoamine Oxidase.\\2016Chemical biology & drug design, May, Volume: 87, Issue:5
Evaluation of Natural and Synthetic 1,4-naphthoquinones as Inhibitors of Monoamine Oxidase.
AID1798473Enzyme Inhibition Assay from Article 10.1021/jm7014155: \\Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (4.65)18.7374
1990's2 (4.65)18.2507
2000's6 (13.95)29.6817
2010's22 (51.16)24.3611
2020's11 (25.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.99 (24.57)
Research Supply Index3.83 (2.92)
Research Growth Index5.23 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.65%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (95.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]